NovaDel Pharma Signs Exclusive License and Distribution Agreement with Rechon Life Science to Manufacture and Commercialize Zolpimist® Outside the US and Canada

Published: Aug 22, 2011

BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

Back to news